Sponsors

Organized By

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. www.alliancerm.org

Sponsor the Program

Interested in gaining exposure to hundreds of leading decision makers in the field? Contact Laura Parsons at lparsons@alliancerm.org for more information on sponsorship and raise your profile at this year’s conference.

In Collaboration With

EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our seven landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, ChinaBio Partnering Forum, Cell & Gene Exchange, and BioEquity Europe) annually attract more than 12,000 senior life science executives who engage in over 43,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. www.ebdgroup.com

Platinum Sponsors

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. The company is organized into two market-focused segments: Pharma and Biotech and Specialty Ingredients. The core competencies that span these segments are advanced manufacturing and quality-control systems, superior regulatory expertise, in-depth market knowledge and extensive technical customer-support and research and development capabilities. www.lonza.com

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo BCT’s Cell Therapy Technologies business enables researchers, developers and manufacturers to create next-generation cell and gene therapies. We do this through flexible, automated solutions that help meet your evolving needs for reproducibility, quality and scale through the phases of development, from translational research to current good manufacturing practice (cGMP) for commercial manufacturing. One example, the Quantum® Cell Expansion System automates and optimizes cell culture to meet the needs of a variety of cell types in a consistent, controlled and functionally closed environment. We are also looking further downstream in the process to provide innovative solutions, like the FINIA® Fill and Finish System, to support your needs into the future. www.terumobct.com

Gold Sponsor

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 180 experts focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. ct.catapult.org.uk | www.gov.uk/innovate-uk

Silver Sponsors

Bio-Techne unites some of life sciences’ most distinguished brands including R&D Systems®, Novus Biologicals®, Tocris Bioscience ®, ProteinSimple® and ACD®. Together they deliver a comprehensive portfolio of high-quality products and technologies tailored to cell therapy development and GMP compliant manufacturing. GMP-grade products: GMP compliant proteins, small molecules, and antibodies suitable for use as ancillary materials in cell therapy manufacturing. CloudzTM T Cell Activation Kit – Technology designed to improve cell activation and selection. Protein analysis platforms – ProteinSimple automated instruments for Simple PlexTM assays, Simple WesternTM assays, Single-Cell Westerns, next generation analytical and iCETM platforms. ELISAs and Luminex® assays – Our Quantikine® and DuoSet® ELISA kits are the gold standard. We are experts in bead-based multiplex assays and provide various high-performance Luminex assays. Custom Development Services – Our custom manufacturing services include GMP-grade proteins and complex media developed to meet your needs. Our scientists work to develop, express, and purify some of the most challenging custom proteins with the highest bioactivities in the market. www.bio-techne.com

Cryoport is the premier provider of temperature controlled logistics solutions to the life sciences industry through our purpose-built proprietary packaging, information technology and specialized logistics expertise. We provide leading-edge temperature controlled logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide including points-of-care, CROs, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. Cryoport’s unparalleled information technology centers around our proprietary Cryoportal® Logistics Management Platform, which facilitates management of the entire shipment process. Our state-of-the-art technology also includes our innovative Smartpak II™ Condition Monitoring System, which provides visibility of the location and the key aspects of critical shipments. The Smartpak II™ works in conjunction with our Cryoportal® to provide real-time information reporting about shipments, integrated condition monitoring, logistics and shipper qualification performance in a single data steam. Cryoport also has a dedicated 24/7/365 customer service team to proactively monitor each shipment, allowing for invention when necessary. www.cryoport.com

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts Phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across six continents, CTI partners with research sites, patients and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America and Asia-Pacific www.ctifacts.com

Medpace is a global full-service clinical research 0rganization (CRO) providing comprehensive development services for drug, biologic and device programs with a specialized focus on advanced therapies including cell and gene therapies. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal and diabetes. With extensive medical expertise, a renowned regulatory affairs department, across six continents, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined and standardized trial management. Learn more about Medpace’s focus on cellular, tissue and gene therapy medicines at www.medpace.com.

MolMed S.p.A. is an Italian biotechnology cell and gene company, focused on research, development, manufacturing and clinical validation of innovative therapies in oncology and rare diseases. MolMed built an original dual business model, based on research and development of proprietary products, and third party GMP services. MolMed is currently the developer and manufacturer for worldwide leaders in the field of gene therapy for rare diseases and allogenic CAR-T therapies supporting their clinical trials and commercial supply. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange and has been managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department and has an operating unit at OpenZone in Bresso. www.molmed.com

World Courier provides unparalleled specialty logistics services to drive the commercial success of our partners around the globe. For 50 years, we’ve delivered peace of mind through world-class supply chain programs, transportation services, storage of time- and temperature-sensitive products, and innovative, cutting-edge medicines including cell and gene therapies. Through our daily work – and powered by our 2,500 associates – we are united in our responsibility to create healthier futures. With a presence in 50+ countries, World Courier is driven by a commitment to excellence, and provides customized solutions with global reach to increase access to care; making us the most trusted specialty logistics company in the world. www.worldcourier.com

Yposkesi is one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe for AAV and lentiviral vector production. A spin-off from the world-class gene therapy pioneer Genethon, Yposkesi capitalizes on more than 20 years’ expertise in biotherapeutic research to offer customers full integrated services; bioprocess development (USP & DSP), from small/pilot to large production scale, analytical development, GMP manufacturing of clinical batches of lentiviral and AAV vectors and regulatory support. Its current 50,000 sq ft (approx. 5,000m2) state-of-the-art facility designed for high efficiency houses four independent manufacturing suites for bulk drug substance and two Fill&Finish suites. Yposkesi is extending this capacity. By 2021 it will double its global footprint to 100,000 ft2 (approx. 10,000m2) with a second large-scale facility designed for commercial production and EMA and FDA compliance. Yposkesi invests significantly in innovation and bioprocessing to deliver on high quality projects, cost-effectively. www.yposkesi.com

Bronze Sponsors

CellGenix is a leading global supplier of high-quality reagents and tools for cell and gene therapy and regenerative medicine applications. As the first company to obtain a GMP manufacturing authorization for cell processing in Europe, we have more than 25 years of expertise in GMP manufacturing and development of cell therapy products. We offer a comprehensive product portfolio in combination with expert regulatory and technical support to ensure a seamless transition from research to commercialization. Our products combine a maximum of quality and safety due to the state-of-the-art production, stringent in-house quality control and comprehensive documentation. https://cellgenix.com

Cobra is a leading international contract development and manufacturing organisation (CDMO) supporting the global cell and gene therapy industry in the development and manufacture of DNA and viral vectors from proof of concept through to clinical trials. We provide a comprehensive service offering, with multi-functional and experienced project teams nurturing customers’ products from preclinical through to clinical GMP manufacture. For cell and gene therapy products we are able to produce DNA (HQ and GMP) and viral vectors (Adenovirus, AAV and Lentiviral vectors). Cobra has also embarked on a £15M operations expansion to fast track our customers’ portfolios through to in-market supply. Check out our updated video on the current expansion. www.cobrabio.com

Invitrx Therapeutics is a leader in birth tissue research and pioneer in the field of regenerative stem cell therapies. Invitrx was established through wound healing funding in 2003 by CEO, Habib Torfi. In this time, Invitx has grown as an innovator of stem cell products and is developing therapies from amniotic stem cells, cord blood stem cells, placental stem cells and Wharton’s jelly stem cells. Our pursuit for innovation has led to a new $7 million facility being opened in Lake Forest, CA in July of 2018. This facility includes three clean rooms, a flow cytometry core and ultracentrifuges. These resources will push for exosomal research. Publishing in renowned journals has illuminated the age of exosomes and these minuscule molecules have the potential to attenuate diseases and possibly improve the quality of life for millions of people. Invitrx hopes to alleviate the symptoms of osteoarthritis and eliminate opioid dependency. www.invitrx.com

Precision BioSciences is a privately held biotechnology company dedicated to improving lives through its next generation gene editing technology, ARCUS. Precision’s approach is based on a proprietary synthetic enzyme, the ARC endonuclease, which features coordinated target site binding and DNA cutting to ensure precise editing outcomes. Uniquely small and monomeric, ARC nucleases are readily delivered to target sites throughout the genome and across cell types and tissues. The value of the ARCUS editing platform is enhanced by Precision’s extensive patent portfolio, established freedom to operate and deep collaborative relationships, positioning Precision to create products that solve significant problems in oncology, genetic disease, agriculture and beyond. Our team includes pioneers in genome engineering and a staff of experienced, committed Precisioneers. Working together in the vibrant innovation center of Durham, NC, we are excited to lead the next wave of medical and scientific possibilities through continuous gene editing innovation. www.precisionbiosciences.com

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, ReNeuron has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. www.reneuron.com

Event Supporters

BioPartner UK is the accredited trade organisation that provides practical support and international promotion to UK Life Sciences companies, who wish to grow their business overseas. BioPartner signposts to UK expertise and leads delegations to promote the UK presence at major international biopharma conferences. By operating in partnership with the UK government and event organisers, BioPartner assists all UK companies with access to government grants and heavily discounted entry fees. Members of the BioPartner Programme receive extra benefits and support to effectively trade overseas. www.biopartner.co.uk

The FreeMind Group is the premier international consulting firm specializing in assisting life science organizations to secure non-dilutive funding from U.S. federal agencies and private foundations. Founded in 1999, The FreeMind Group is the largest consulting group of its kind and works with a variety of life sciences organizations, from small startups to large pharmaceutical companies. FreeMind’s proven long-term strategic approach has garnered its clients over $1.5 billion to date in non-dilutive funding. The FreeMind team combines their extraordinary scientific understanding, innovative business and financial expertise and creative writing and presentation skills to cater to the specific and unique needs of academic and research institutions as well as the life science industry. www.freemindconsultants.com

By using this website you agree to accept our Privacy Policy and Terms & Conditions